Loading…
Thoracic radiation therapy improves the overall survival of patients with extensive‐stage small cell lung cancer with distant metastasis
BACKGROUND: The authors conducted a retrospective study to evaluate the effects of thoracic radiation therapy (TRT) for patients with extensive‐stage small cell lung cancer (ED‐SCLC). METHODS: Between January 2003 and December 2006, the records of 119 patients who were diagnosed with ED‐SCLC (all wi...
Saved in:
Published in: | Cancer 2011-12, Vol.117 (23), p.5423-5431 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4276-e4c5aecce90366697053868edcb72c8809ea808a4c98b2bb7fdf50bb67be215c3 |
---|---|
cites | cdi_FETCH-LOGICAL-c4276-e4c5aecce90366697053868edcb72c8809ea808a4c98b2bb7fdf50bb67be215c3 |
container_end_page | 5431 |
container_issue | 23 |
container_start_page | 5423 |
container_title | Cancer |
container_volume | 117 |
creator | Zhu, Hui Zhou, Zongmei Wang, Yan Bi, Nan Feng, Qinfu Li, Junling Lv, Jima Chen, Dongfu Shi, Yuankai Wang, Luhua |
description | BACKGROUND:
The authors conducted a retrospective study to evaluate the effects of thoracic radiation therapy (TRT) for patients with extensive‐stage small cell lung cancer (ED‐SCLC).
METHODS:
Between January 2003 and December 2006, the records of 119 patients who were diagnosed with ED‐SCLC (all with distant metastasis [M1]) were included in the study. Sixty patients received chemotherapy (ChT) and TRT (ChT/TRT), and 59 patients received ChT alone. The ChT regimens consisted of either carboplatin and etoposide (CE) or cisplatin and etoposide (PE). The total dose of TRT ranged from 40 to 60 grays (Gy) at 1.8 to 2.0 Gy per fraction.
RESULTS:
For the entire group, the median survival was 13 months, and the 2‐year and 5‐year overall survival (OS) rates were 26.1% and 6.5%, respectively. The median survival and the 2‐year and 5‐year OS rates were 17 months, 35%, and 7.1%, respectively, in the ChT/TRT group and 9.3 months, 17%, and 5.1%, respectively, in the ChT group (P = .014). However, this improvement was achieved at the expense of low toxicity. Multivariate analysis revealed that receiving ≥4 cycles of ChT (P = .032) and TRT (P = .005) were favorable prognostic factors for OS. Of all toxicities, only high‐grade leucopenia (grade >3) was more frequent in the ChT/TRT group.
CONCLUSIONS:
The addition of TRT to ChT improved the OS of patients with ED‐SCLC. Furthermore, receiving ≥4 cycles of ChT and TRT were independent, favorable prognostic factors for OS. Cancer 2011;. © 2011 American Cancer Society.
The addition of thoracic radiation therapy (TRT) to chemotherapy (ChT) improved the overall survival (OS) of patients with extensive‐stage small cell lung cancer. The receipt of ≥4 cycles of ChT and/or TRT was an independent, favorable prognostic factor for OS. |
doi_str_mv | 10.1002/cncr.26206 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1492615663</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1492615663</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4276-e4c5aecce90366697053868edcb72c8809ea808a4c98b2bb7fdf50bb67be215c3</originalsourceid><addsrcrecordid>eNp9kM1u1DAQgK0KRJfCpQ-AfEGqkNKOncROjmhVfqQKJNRK3CLHmXSN8rP1ONvujTMnnpEnwSFbuHHxjEefZzwfY6cCzgWAvLCD9edSSVBHbCWg1AmITD5hKwAokjxLvx6z50Tf4lXLPH3GjqXIVSq0WrEf15vRG-ss96ZxJrhx4GGD3mz33PVbP-6Q5gKPiTddx2nyO7czHR9bvo08DoH4vQsbjg8BB3I7_PX9JwVzi5z6-YXFeHTTcMutGSz6hW5cZIbAewwmZuToBXvamo7w5SGesJt3l9frD8nV5_cf12-vEptJrRLMbG7QWiwhVUqVGvK0UAU2ttbSFgWUaAooTGbLopZ1rdumzaGula4x7m3TE3a29I3b3U1IoeodzZ80A44TVSIrpYqCVBrRNwtq_Ujksa223vXG7ysB1ey-mt1Xf9xH-NWh71T32PxFH2VH4PUBMGRN1_qow9E_LtNaSIDIiYW7dx3u_zOyWn9af1mG_wZZI6DB</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1492615663</pqid></control><display><type>article</type><title>Thoracic radiation therapy improves the overall survival of patients with extensive‐stage small cell lung cancer with distant metastasis</title><source>Wiley-Blackwell Read & Publish Collection</source><source>EZB Electronic Journals Library</source><creator>Zhu, Hui ; Zhou, Zongmei ; Wang, Yan ; Bi, Nan ; Feng, Qinfu ; Li, Junling ; Lv, Jima ; Chen, Dongfu ; Shi, Yuankai ; Wang, Luhua</creator><creatorcontrib>Zhu, Hui ; Zhou, Zongmei ; Wang, Yan ; Bi, Nan ; Feng, Qinfu ; Li, Junling ; Lv, Jima ; Chen, Dongfu ; Shi, Yuankai ; Wang, Luhua</creatorcontrib><description>BACKGROUND:
The authors conducted a retrospective study to evaluate the effects of thoracic radiation therapy (TRT) for patients with extensive‐stage small cell lung cancer (ED‐SCLC).
METHODS:
Between January 2003 and December 2006, the records of 119 patients who were diagnosed with ED‐SCLC (all with distant metastasis [M1]) were included in the study. Sixty patients received chemotherapy (ChT) and TRT (ChT/TRT), and 59 patients received ChT alone. The ChT regimens consisted of either carboplatin and etoposide (CE) or cisplatin and etoposide (PE). The total dose of TRT ranged from 40 to 60 grays (Gy) at 1.8 to 2.0 Gy per fraction.
RESULTS:
For the entire group, the median survival was 13 months, and the 2‐year and 5‐year overall survival (OS) rates were 26.1% and 6.5%, respectively. The median survival and the 2‐year and 5‐year OS rates were 17 months, 35%, and 7.1%, respectively, in the ChT/TRT group and 9.3 months, 17%, and 5.1%, respectively, in the ChT group (P = .014). However, this improvement was achieved at the expense of low toxicity. Multivariate analysis revealed that receiving ≥4 cycles of ChT (P = .032) and TRT (P = .005) were favorable prognostic factors for OS. Of all toxicities, only high‐grade leucopenia (grade >3) was more frequent in the ChT/TRT group.
CONCLUSIONS:
The addition of TRT to ChT improved the OS of patients with ED‐SCLC. Furthermore, receiving ≥4 cycles of ChT and TRT were independent, favorable prognostic factors for OS. Cancer 2011;. © 2011 American Cancer Society.
The addition of thoracic radiation therapy (TRT) to chemotherapy (ChT) improved the overall survival (OS) of patients with extensive‐stage small cell lung cancer. The receipt of ≥4 cycles of ChT and/or TRT was an independent, favorable prognostic factor for OS.</description><identifier>ISSN: 0008-543X</identifier><identifier>ISSN: 1097-0142</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.26206</identifier><identifier>PMID: 21563176</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Carboplatin ; Carcinoma, Small Cell - mortality ; Carcinoma, Small Cell - pathology ; Carcinoma, Small Cell - radiotherapy ; Chemoradiotherapy ; chemotherapy cycle ; extensive‐stage small cell lung cancer ; Female ; Humans ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Lung Neoplasms - radiotherapy ; Male ; Medical sciences ; Middle Aged ; Neoplasm Metastasis ; overall survival ; Pneumology ; Prognosis ; prognosis factor ; Retrospective Studies ; thoracic radiation therapy ; Treatment Failure ; Tumors ; Tumors of the respiratory system and mediastinum</subject><ispartof>Cancer, 2011-12, Vol.117 (23), p.5423-5431</ispartof><rights>Copyright © 2011 American Cancer Society</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 American Cancer Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4276-e4c5aecce90366697053868edcb72c8809ea808a4c98b2bb7fdf50bb67be215c3</citedby><cites>FETCH-LOGICAL-c4276-e4c5aecce90366697053868edcb72c8809ea808a4c98b2bb7fdf50bb67be215c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24771200$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21563176$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhu, Hui</creatorcontrib><creatorcontrib>Zhou, Zongmei</creatorcontrib><creatorcontrib>Wang, Yan</creatorcontrib><creatorcontrib>Bi, Nan</creatorcontrib><creatorcontrib>Feng, Qinfu</creatorcontrib><creatorcontrib>Li, Junling</creatorcontrib><creatorcontrib>Lv, Jima</creatorcontrib><creatorcontrib>Chen, Dongfu</creatorcontrib><creatorcontrib>Shi, Yuankai</creatorcontrib><creatorcontrib>Wang, Luhua</creatorcontrib><title>Thoracic radiation therapy improves the overall survival of patients with extensive‐stage small cell lung cancer with distant metastasis</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND:
The authors conducted a retrospective study to evaluate the effects of thoracic radiation therapy (TRT) for patients with extensive‐stage small cell lung cancer (ED‐SCLC).
METHODS:
Between January 2003 and December 2006, the records of 119 patients who were diagnosed with ED‐SCLC (all with distant metastasis [M1]) were included in the study. Sixty patients received chemotherapy (ChT) and TRT (ChT/TRT), and 59 patients received ChT alone. The ChT regimens consisted of either carboplatin and etoposide (CE) or cisplatin and etoposide (PE). The total dose of TRT ranged from 40 to 60 grays (Gy) at 1.8 to 2.0 Gy per fraction.
RESULTS:
For the entire group, the median survival was 13 months, and the 2‐year and 5‐year overall survival (OS) rates were 26.1% and 6.5%, respectively. The median survival and the 2‐year and 5‐year OS rates were 17 months, 35%, and 7.1%, respectively, in the ChT/TRT group and 9.3 months, 17%, and 5.1%, respectively, in the ChT group (P = .014). However, this improvement was achieved at the expense of low toxicity. Multivariate analysis revealed that receiving ≥4 cycles of ChT (P = .032) and TRT (P = .005) were favorable prognostic factors for OS. Of all toxicities, only high‐grade leucopenia (grade >3) was more frequent in the ChT/TRT group.
CONCLUSIONS:
The addition of TRT to ChT improved the OS of patients with ED‐SCLC. Furthermore, receiving ≥4 cycles of ChT and TRT were independent, favorable prognostic factors for OS. Cancer 2011;. © 2011 American Cancer Society.
The addition of thoracic radiation therapy (TRT) to chemotherapy (ChT) improved the overall survival (OS) of patients with extensive‐stage small cell lung cancer. The receipt of ≥4 cycles of ChT and/or TRT was an independent, favorable prognostic factor for OS.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carboplatin</subject><subject>Carcinoma, Small Cell - mortality</subject><subject>Carcinoma, Small Cell - pathology</subject><subject>Carcinoma, Small Cell - radiotherapy</subject><subject>Chemoradiotherapy</subject><subject>chemotherapy cycle</subject><subject>extensive‐stage small cell lung cancer</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - radiotherapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>overall survival</subject><subject>Pneumology</subject><subject>Prognosis</subject><subject>prognosis factor</subject><subject>Retrospective Studies</subject><subject>thoracic radiation therapy</subject><subject>Treatment Failure</subject><subject>Tumors</subject><subject>Tumors of the respiratory system and mediastinum</subject><issn>0008-543X</issn><issn>1097-0142</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp9kM1u1DAQgK0KRJfCpQ-AfEGqkNKOncROjmhVfqQKJNRK3CLHmXSN8rP1ONvujTMnnpEnwSFbuHHxjEefZzwfY6cCzgWAvLCD9edSSVBHbCWg1AmITD5hKwAokjxLvx6z50Tf4lXLPH3GjqXIVSq0WrEf15vRG-ss96ZxJrhx4GGD3mz33PVbP-6Q5gKPiTddx2nyO7czHR9bvo08DoH4vQsbjg8BB3I7_PX9JwVzi5z6-YXFeHTTcMutGSz6hW5cZIbAewwmZuToBXvamo7w5SGesJt3l9frD8nV5_cf12-vEptJrRLMbG7QWiwhVUqVGvK0UAU2ttbSFgWUaAooTGbLopZ1rdumzaGula4x7m3TE3a29I3b3U1IoeodzZ80A44TVSIrpYqCVBrRNwtq_Ujksa223vXG7ysB1ey-mt1Xf9xH-NWh71T32PxFH2VH4PUBMGRN1_qow9E_LtNaSIDIiYW7dx3u_zOyWn9af1mG_wZZI6DB</recordid><startdate>20111201</startdate><enddate>20111201</enddate><creator>Zhu, Hui</creator><creator>Zhou, Zongmei</creator><creator>Wang, Yan</creator><creator>Bi, Nan</creator><creator>Feng, Qinfu</creator><creator>Li, Junling</creator><creator>Lv, Jima</creator><creator>Chen, Dongfu</creator><creator>Shi, Yuankai</creator><creator>Wang, Luhua</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>20111201</creationdate><title>Thoracic radiation therapy improves the overall survival of patients with extensive‐stage small cell lung cancer with distant metastasis</title><author>Zhu, Hui ; Zhou, Zongmei ; Wang, Yan ; Bi, Nan ; Feng, Qinfu ; Li, Junling ; Lv, Jima ; Chen, Dongfu ; Shi, Yuankai ; Wang, Luhua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4276-e4c5aecce90366697053868edcb72c8809ea808a4c98b2bb7fdf50bb67be215c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carboplatin</topic><topic>Carcinoma, Small Cell - mortality</topic><topic>Carcinoma, Small Cell - pathology</topic><topic>Carcinoma, Small Cell - radiotherapy</topic><topic>Chemoradiotherapy</topic><topic>chemotherapy cycle</topic><topic>extensive‐stage small cell lung cancer</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - radiotherapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>overall survival</topic><topic>Pneumology</topic><topic>Prognosis</topic><topic>prognosis factor</topic><topic>Retrospective Studies</topic><topic>thoracic radiation therapy</topic><topic>Treatment Failure</topic><topic>Tumors</topic><topic>Tumors of the respiratory system and mediastinum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhu, Hui</creatorcontrib><creatorcontrib>Zhou, Zongmei</creatorcontrib><creatorcontrib>Wang, Yan</creatorcontrib><creatorcontrib>Bi, Nan</creatorcontrib><creatorcontrib>Feng, Qinfu</creatorcontrib><creatorcontrib>Li, Junling</creatorcontrib><creatorcontrib>Lv, Jima</creatorcontrib><creatorcontrib>Chen, Dongfu</creatorcontrib><creatorcontrib>Shi, Yuankai</creatorcontrib><creatorcontrib>Wang, Luhua</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhu, Hui</au><au>Zhou, Zongmei</au><au>Wang, Yan</au><au>Bi, Nan</au><au>Feng, Qinfu</au><au>Li, Junling</au><au>Lv, Jima</au><au>Chen, Dongfu</au><au>Shi, Yuankai</au><au>Wang, Luhua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Thoracic radiation therapy improves the overall survival of patients with extensive‐stage small cell lung cancer with distant metastasis</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2011-12-01</date><risdate>2011</risdate><volume>117</volume><issue>23</issue><spage>5423</spage><epage>5431</epage><pages>5423-5431</pages><issn>0008-543X</issn><issn>1097-0142</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND:
The authors conducted a retrospective study to evaluate the effects of thoracic radiation therapy (TRT) for patients with extensive‐stage small cell lung cancer (ED‐SCLC).
METHODS:
Between January 2003 and December 2006, the records of 119 patients who were diagnosed with ED‐SCLC (all with distant metastasis [M1]) were included in the study. Sixty patients received chemotherapy (ChT) and TRT (ChT/TRT), and 59 patients received ChT alone. The ChT regimens consisted of either carboplatin and etoposide (CE) or cisplatin and etoposide (PE). The total dose of TRT ranged from 40 to 60 grays (Gy) at 1.8 to 2.0 Gy per fraction.
RESULTS:
For the entire group, the median survival was 13 months, and the 2‐year and 5‐year overall survival (OS) rates were 26.1% and 6.5%, respectively. The median survival and the 2‐year and 5‐year OS rates were 17 months, 35%, and 7.1%, respectively, in the ChT/TRT group and 9.3 months, 17%, and 5.1%, respectively, in the ChT group (P = .014). However, this improvement was achieved at the expense of low toxicity. Multivariate analysis revealed that receiving ≥4 cycles of ChT (P = .032) and TRT (P = .005) were favorable prognostic factors for OS. Of all toxicities, only high‐grade leucopenia (grade >3) was more frequent in the ChT/TRT group.
CONCLUSIONS:
The addition of TRT to ChT improved the OS of patients with ED‐SCLC. Furthermore, receiving ≥4 cycles of ChT and TRT were independent, favorable prognostic factors for OS. Cancer 2011;. © 2011 American Cancer Society.
The addition of thoracic radiation therapy (TRT) to chemotherapy (ChT) improved the overall survival (OS) of patients with extensive‐stage small cell lung cancer. The receipt of ≥4 cycles of ChT and/or TRT was an independent, favorable prognostic factor for OS.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>21563176</pmid><doi>10.1002/cncr.26206</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0008-543X |
ispartof | Cancer, 2011-12, Vol.117 (23), p.5423-5431 |
issn | 0008-543X 1097-0142 1097-0142 |
language | eng |
recordid | cdi_proquest_miscellaneous_1492615663 |
source | Wiley-Blackwell Read & Publish Collection; EZB Electronic Journals Library |
subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Carboplatin Carcinoma, Small Cell - mortality Carcinoma, Small Cell - pathology Carcinoma, Small Cell - radiotherapy Chemoradiotherapy chemotherapy cycle extensive‐stage small cell lung cancer Female Humans Lung Neoplasms - mortality Lung Neoplasms - pathology Lung Neoplasms - radiotherapy Male Medical sciences Middle Aged Neoplasm Metastasis overall survival Pneumology Prognosis prognosis factor Retrospective Studies thoracic radiation therapy Treatment Failure Tumors Tumors of the respiratory system and mediastinum |
title | Thoracic radiation therapy improves the overall survival of patients with extensive‐stage small cell lung cancer with distant metastasis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T14%3A12%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Thoracic%20radiation%20therapy%20improves%20the%20overall%20survival%20of%20patients%20with%20extensive%E2%80%90stage%20small%20cell%20lung%20cancer%20with%20distant%20metastasis&rft.jtitle=Cancer&rft.au=Zhu,%20Hui&rft.date=2011-12-01&rft.volume=117&rft.issue=23&rft.spage=5423&rft.epage=5431&rft.pages=5423-5431&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/cncr.26206&rft_dat=%3Cproquest_cross%3E1492615663%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4276-e4c5aecce90366697053868edcb72c8809ea808a4c98b2bb7fdf50bb67be215c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1492615663&rft_id=info:pmid/21563176&rfr_iscdi=true |